NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital Portfolio Company Odyssey Therapeutics Successfully Completes Upsized IPO on NASDAQ, Raising a Total of $304 million
Jeito[1] reaffirms its commitment by participating in the IPO, following its significant investment in Odyssey’s recent oversubscribed $213 million series D financing round This renewed support underscores the company’s innovation potential for patients with...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Dr Rafaèle Tordjman Receives L’Agefi’s Prestigious 2024 ‘AM Leader’ Award
Paris, France, November 22nd 2024 - Jeito is pleased to announce that Dr Rafaèle Tordjman has...
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 (CLDN1) ADCs in solid tumors
Building on its co-lead investments in Alentis Therapeutics’ Series B (2021) and Series C (2023)...
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
This new financing will support broad late-stage clinical development program for visugromab,...
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
This acquisition reflects the significant clinical progress achieved with Restoret™,EyeBio’s novel...
Jeito Capital announces acquisition of portfolio company HI-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion; Biogen to strengthen portfolio to help patients with severe immune-mediated disease
Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion...
EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting
Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.